V8 Peptides — Engineered Performance
Research Library
PT-141 Structure-Activity: Nle, D-Phe and the Ring
PT-141Chemistry

PT-141 Structure-Activity: Nle, D-Phe and the Ring

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What structural changes make PT-141 what it is? Four changes to the α-MSH template: norleucine for methionine, D-phenylalanine at position 7, a lactam ring between Asp and Lys, and a free-acid C-terminus. The first two were shown in early work to extend activity and potency in bioassays; ring geometry can shift selectivity; effects of the C-terminus must be measured. Supplied for laboratory research use only.

PT-141 is the product of decades of medicinal chemistry on a single hormone. Starting from α-melanocyte-stimulating hormone, a 13-residue peptide, chemists changed one residue at a time, closed a ring, and trimmed the chain until a seven-residue cyclic molecule remained that is more potent, more stable and easier to handle than its natural template. Reading PT-141 through that lens, as a set of deliberate modifications, is the clearest way to understand why it behaves the way it does in the laboratory. This article goes modification by modification and says, for each, what the published evidence shows and where the evidence stops.

The sequence on the V8 PT-141 product page is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with formula C50H68N14O10 and a 10 mg lyophilized vial supplied for laboratory research use only. Four features of that string carry the structure-activity story: the N-terminal acetyl and norleucine, the D-phenylalanine, the Asp–Lys lactam bridge, and the free acid at the C-terminus. The companion PT-141 research overview covers general background; sourcing questions are in where to buy PT-141.

The starting point: the α-MSH message sequence

The natural hormone α-MSH is a linear tridecapeptide whose central residues His-Phe-Arg-Trp are the part of the molecule that melanocortin receptors recognize most directly. In the sequence of PT-141 that tetrad survives as His-D-Phe-Arg-Trp, flanked by the ring-closing residues. This conservation is the reason the analog is useful: it speaks the receptors' language, while the changes around it alter stability and conformation. A pharmacology review of the receptor family explains that the five subtypes share a seven-transmembrane architecture and respond to melanocortin peptides through cyclic AMP, with each subtype distributed differently across tissues (Yang, 2011). Structure-activity work is therefore about tuning how a conserved message is presented to a family of related receptors, not about inventing a new one.

Modification 1: norleucine for methionine

Native α-MSH contains methionine at position 4. Methionine's thioether is prone to oxidation, which changes the peptide's polarity and can alter its activity. Replacing it with norleucine, an isosteric straight-chain residue with a methylene group where methionine has sulfur, removes that liability without changing the side-chain shape. The early analog work that introduced this swap was published by Sawyer and colleagues in 1980, who made [Nle4]-α-MSH and found that it, like heat-alkali-exposed α-MSH, showed prolonged activity in the frog-skin assay (Sawyer et al., 1980). Practical consequence for the lab: a norleucine-containing analog has no methionine sulfoxide route, one fewer thing for the quality control analyst to chase on a chromatogram.

Modification 2: D-phenylalanine at position 7

The same 1980 paper reported that adding a second change, D-phenylalanine in place of L-phenylalanine at position 7, gave [Nle4, D-Phe7]-α-MSH, an analog that was resistant to degradation by serum enzymes and was 26 times as potent as α-MSH in the adenylate cyclase assay in mouse melanoma preparations, with markedly increased activity in the frog-skin bioassay and in tyrosinase stimulation (Sawyer et al., 1980). The authors proposed it as a molecular probe for melanotropin receptors. Two effects combine here. Peptidases are stereospecific and tend to cleave poorly next to D-residues, which increases persistence. And the D-configuration changes the backbone turn that presents the neighbouring Arg-Trp, which, in later cyclic analogs, is stabilized by the ring. PT-141 inherits the D-Phe unchanged.

Modification 3: the lactam ring

Linear peptides are floppy. Cyclizing the chain between two side groups reduces the number of shapes a peptide can take and, if the retained shape is a good fit for the receptor, raises affinity. A 1989 Journal of the American Chemical Society paper reported the design of a class of superpotent cyclic α-melanotropins based on quenched dynamic simulations (Al-Obeidi et al., 1989); the design principle was to engineer a conformation computationally and then close it chemically. PT-141 and melanotan II use an amide (lactam) bridge between the side chains of aspartic acid and lysine, which, unlike a disulfide, does not break under reducing conditions. That is a handling-relevant fact, because a lab can include reducing agents in a buffer without opening this ring, whereas it would open a disulfide-bridged analog.

Ring size and position matter, and the literature shows how sensitive selectivity can be. A medicinal chemistry paper from 2006 used the melanotan II NMR structure as a template, built disulfide or lactam bridges between residues 5 and 8 to hold the β-turn spanning His6 and D-Phe7, and obtained analogs with good binding to human MC4R (0.7–4.1 nM) but no binding up to 10 µM at MC1R, MC3R and MC5R (Ying et al., 2006). Those analogs behaved as MC4R antagonists, and the authors attributed the selectivity partly to strong conformational constraint from ring contraction relative to melanotan II. The lesson is that a ring is a dial, not a switch: small geometric changes can move a molecule from broad agonist to selective antagonist.

Modification 4: the C-terminus

The difference between PT-141 and melanotan II is a single terminal group: the free carboxylic acid of PT-141 versus the primary amide of melanotan II. A historical review lists PT-141 as a new analog of melanotan II (Hadley and Dorr, 2006). In chemical terms, an amide is neutral at physiological pH, while a carboxylic acid is ionized there, so the two molecules differ in net charge, in hydrogen-bonding pattern at one end and in their susceptibility to carboxypeptidases. How much that matters for receptor binding depends on the subtype and has to be measured. This article does not quote selectivity differences, because the values reported in the literature were generated in different cell systems and cannot be compared across studies without caveats. What can be said safely is that the C-terminus is the only structural variable between the two commercially listed molecules, which makes the pair a natural matched set for a controlled experiment; the comparison is developed in PT-141 vs melanotan II.

A summary table of the modifications

The table lines the four modifications up against the reasons the field made them, with the evidence cited above.

FeatureChange from α-MSHReported or expected consequenceEvidence in this article
Position 4Met → norleucineRemoves the oxidizable thioether; prolonged activity in a bioassaySawyer et al., 1980
Position 7L-Phe → D-PheResistance to serum enzymes; 26-fold greater potency in an adenylate cyclase assay in mouse melanoma preparationsSawyer et al., 1980
CoreLinear → lactam-bridged cycleConformational restriction; superpotent designs; ring size can switch agonist to antagonistAl-Obeidi et al., 1989; Ying et al., 2006
C-terminusAmide (melanotan II) → free acid (PT-141)Different net charge and hydrogen bonding; effect on receptor profile must be measuredProduct-page sequences; Hadley and Dorr, 2006

Consequences for handling and analysis

Each modification leaves a mark on the analytical profile. Norleucine and D-phenylalanine are not natural at those positions, so a method that tries to confirm sequence by enzymatic digestion has to account for stereochemistry. Because the ring is a lactam, reducing conditions do not open it, but strongly acidic or basic conditions over long times can hydrolyze amide bonds in general. The tryptophan and histidine residues are chromophores and sites of oxidation and photodegradation, which is one reason for the product page guidance to protect the vial from light, moisture and heat. Storage at 2–8 °C, with −20 °C for the long term, is the page's stated recommendation; the general logic is described in storing research peptides.

Quality testing follows from the same logic. Truncated or racemized impurities arise during synthesis, and chromatographic methods differ in how well they resolve them from the main species; the review of related impurities in peptide medicines describes how (D'Hondt et al., 2014). The table below maps each feature to the analytical question it raises.

FeatureAnalytical questionWhy it is asked
Norleucine (position 4)Is the residue norleucine and not methionine or leucine?Isobaric or near-isobaric residues need sequence-level confirmation
D-Phe (position 7)Is the stereochemistry preserved?Racemization during synthesis can produce diastereomers that elute close to the main peak
Lactam ringIs the ring closed and monomeric?Open-chain and dimeric species are plausible by-products of cyclization
Free acid C-terminusIs it acid and not amide?The two terminal forms differ by about one dalton

A purity percentage by HPLC is meaningful only when the method is stated, and identity confirmation requires mass resolution fine enough to see a one-dalton difference when the question is acid versus amide. See {A("/research/pt-141-purity-testing","PT-141 purity testing")} and {A("/research/understanding-hplc-purity","understanding HPLC purity")}.

What structure-activity data cannot tell you

Structure-activity relationships are inferences from sets of molecules measured in the same system. They do not transfer cleanly across cell lines, receptor species or assay formats, and they say nothing about what a compound does in a whole organism. Several reported properties of related analogs, for example the potency multiples above, come from bioassays and cell preparations of specific species. A laboratory that wants to claim a structure-activity relationship for PT-141 needs its own matched set, including the reference compounds that bracket it, tested in one system with the lot recorded. The parent molecule is described in the melanotan II research overview. Documentation for the V8 material is described on the COA page, and the catalogue is on the shop page.

Frequently asked questions

What are the key structural features of PT-141?

A seven-residue cyclic peptide with an N-terminal acetyl and norleucine, a His-D-Phe-Arg-Trp core, a lactam bridge between aspartic acid and lysine side chains, and a free carboxylic acid at the C-terminus.

Why is norleucine used instead of methionine?

Methionine contains an oxidizable thioether. Norleucine has the same shape without the sulfur, so the analog avoids that oxidation route. The substitution was used in early α-MSH analogs (Sawyer et al., 1980).

What does D-phenylalanine add?

In the 1980 study, [Nle4, D-Phe7]-α-MSH resisted serum enzymes and was 26 times as potent as α-MSH in the mouse melanoma adenylate cyclase assay (Sawyer et al., 1980).

Is the lactam ring sensitive to reducing agents?

No. A lactam is an amide bond, so reducing agents such as DTT or TCEP do not open it, unlike a disulfide bridge. Other conditions, such as extreme pH over long periods, can still damage amide bonds.

How does ring size affect melanocortin receptor selectivity?

One study built bridges between residues 5 and 8 to constrain the His-D-Phe turn and obtained MC4R-selective analogs that behaved as antagonists (Ying et al., 2006), showing that ring geometry can change both selectivity and efficacy.

How does PT-141 differ from melanotan II structurally?

Only at the C-terminus: PT-141 has a free carboxylic acid and melanotan II has a primary amide, according to the sequences on the two V8 product pages.

Do the structure-activity findings transfer to PT-141 directly?

Not automatically. Several cited findings concern related analogs, and potencies vary with the assay system. PT-141 needs its own measurements under the lab's conditions.

Which residues are most prone to degradation in PT-141?

Tryptophan and histidine are susceptible to oxidation and light-driven damage in peptides generally. This is consistent with the storage guidance to protect the vial from light, moisture and heat.

What storage conditions does the product page give for PT-141?

Refrigerate at 2–8 °C, use −20 °C for long-term storage, and protect from heat, moisture and light.

Is PT-141 sold for use outside the laboratory?

No. It is supplied strictly for laboratory research use only and is not intended for human or animal consumption.

Related reading: PT-141 vs MT-2: Formula, Mass and Analytical Differences, PT-141 vs MT-2: Choosing a Melanocortin Reference Ligand, PT-141 Reconstitution for In Vitro Assays.

References

  1. Sawyer TK, Sanfilippo PJ, Hruby VJ, et al. 4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity. Proc Natl Acad Sci U S A. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754
  2. Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. Design of a new class of superpotent cyclic α-melanotropins based on quenched dynamic simulations. J Am Chem Soc. 1989;111(9):3413-3416. doi:10.1021/ja00191a044
  3. Ying J, Kover KE, Gu X, et al. Design, synthesis, and biological evaluation of new cyclic melanotropin peptide analogues selective for the human melanocortin-4 receptor. J Med Chem. 2006;49(23):6888-6896. doi:10.1021/jm060768f
  4. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029
  5. Yang Y. Structure, function and regulation of the melanocortin receptors. Eur J Pharmacol. 2011;660(1):125-130. doi:10.1016/j.ejphar.2010.12.020
  6. D'Hondt M, Bracke N, Taevernier L, et al. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014;101:2-30. doi:10.1016/j.jpba.2014.06.012

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.